<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7457942\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="resource centre remains active. Abstract Humans have been suffered from" exact="viral" post="infections over the centuries, such as influenza, HSV, and"/>
  <result pre="centre remains active. Abstract Humans have been suffered from viral" exact="infections" post="over the centuries, such as influenza, HSV, and HIV,"/>
  <result pre="of people worldwide. However, the availability of effective treatments for" exact="infectious diseases" post="remains limited until now, as most of the viral"/>
  <result pre="However, the availability of effective treatments for infectious diseases remains" exact="limited" post="until now, as most of the viral pathogens resisted"/>
  <result pre="infectious diseases remains limited until now, as most of the" exact="viral" post="pathogens resisted to many medical treatments. Marine microbes are"/>
  <result pre="antivirus agents. To date, a large number of marine microbial" exact="secondary" post="metabolites with antiviral activities have been widely reported. In"/>
  <result pre="Antivirus Anti-influenza Anti-HSV Anti-HIV Abbreviations HSV, Herpes simplex HIV, Human" exact="immunodeficiency" post="virus HCV, Hepatitis C virus RSV, Respiratory syncytial virus"/>
  <result pre="Anti-HIV Abbreviations HSV, Herpes simplex HIV, Human immunodeficiency virus HCV," exact="Hepatitis" post="C virus RSV, Respiratory syncytial virus EV71, Enterovirus 71"/>
  <result pre="simplex HIV, Human immunodeficiency virus HCV, Hepatitis C virus RSV," exact="Respiratory" post="syncytial virus EV71, Enterovirus 71 DENV, Dengue virus COVID-19,"/>
  <result pre="C virus RSV, Respiratory syncytial virus EV71, Enterovirus 71 DENV," exact="Dengue" post="virus COVID-19, Coronavirus disease 2019 SARS-CoV-2, Severe acute respiratory"/>
  <result pre="syncytial virus EV71, Enterovirus 71 DENV, Dengue virus COVID-19, Coronavirus" exact="disease" post="2019 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 CHIKV,"/>
  <result pre="Enterovirus 71 DENV, Dengue virus COVID-19, Coronavirus disease 2019 SARS-CoV-2," exact="Severe" post="acute respiratory syndrome coronavirus 2 CHIKV, Chikungunya virus WEEV,"/>
  <result pre="71 DENV, Dengue virus COVID-19, Coronavirus disease 2019 SARS-CoV-2, Severe" exact="acute" post="respiratory syndrome coronavirus 2 CHIKV, Chikungunya virus WEEV, Western"/>
  <result pre="DENV, Dengue virus COVID-19, Coronavirus disease 2019 SARS-CoV-2, Severe acute" exact="respiratory" post="syndrome coronavirus 2 CHIKV, Chikungunya virus WEEV, Western equine"/>
  <result pre="Dengue virus COVID-19, Coronavirus disease 2019 SARS-CoV-2, Severe acute respiratory" exact="syndrome" post="coronavirus 2 CHIKV, Chikungunya virus WEEV, Western equine encephalitis"/>
  <result pre="Severe acute respiratory syndrome coronavirus 2 CHIKV, Chikungunya virus WEEV," exact="Western equine encephalitis" post="virus CPE, Cythopathic effect 1 Introduction As we all"/>
  <result pre="respiratory syndrome coronavirus 2 CHIKV, Chikungunya virus WEEV, Western equine" exact="encephalitis" post="virus CPE, Cythopathic effect 1 Introduction As we all"/>
  <result pre="virus CPE, Cythopathic effect 1 Introduction As we all know," exact="viral" post="infections are the main reasons for human death worldwide"/>
  <result pre="CPE, Cythopathic effect 1 Introduction As we all know, viral" exact="infections" post="are the main reasons for human death worldwide [1]."/>
  <result pre="are the main reasons for human death worldwide [1]. Several" exact="infectious" post="viral diseases occurred so far have been reported, which"/>
  <result pre="the main reasons for human death worldwide [1]. Several infectious" exact="viral" post="diseases occurred so far have been reported, which involve"/>
  <result pre="such as influenza [2], Herpes Simplex Virus (HSV) [3], Human" exact="Immunodeficiency" post="Virus (HIV) [4], Respiratory Syncytial Virus (RSV) [5], Enterovirus"/>
  <result pre="Herpes Simplex Virus (HSV) [3], Human Immunodeficiency Virus (HIV) [4]," exact="Respiratory" post="Syncytial Virus (RSV) [5], Enterovirus 71 (EV71) [6], Dengue"/>
  <result pre="[4], Respiratory Syncytial Virus (RSV) [5], Enterovirus 71 (EV71) [6]," exact="Dengue" post="Virus (DENV) [7], Ebola Virus [8], as well as"/>
  <result pre="Ebola Virus [8], as well as the recently emerging coronavirus" exact="disease" post="2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus"/>
  <result pre="the recently emerging coronavirus disease 2019 (COVID-19) caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [9]. The main characteristic"/>
  <result pre="recently emerging coronavirus disease 2019 (COVID-19) caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [9]. The main characteristic of"/>
  <result pre="emerging coronavirus disease 2019 (COVID-19) caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [9]. The main characteristic of viruses"/>
  <result pre="their genomes are easily mutated, making it difficult to control" exact="viral" post="infections and causing pandemics worldwide. Meanwhile, in the absence"/>
  <result pre="genomes are easily mutated, making it difficult to control viral" exact="infections" post="and causing pandemics worldwide. Meanwhile, in the absence of"/>
  <result pre="control viral infections and causing pandemics worldwide. Meanwhile, in the" exact="absence of" post="vaccines and antiviral therapies, the rapid spread of the"/>
  <result pre="most antiviral drugs today have adverse drug reactions and develop" exact="viral" post="resistance to treatments. The threat of drug resistance not"/>
  <result pre="only results in huge challenges to the clinical management of" exact="viral" post="infections, but also places a heavy burden on the"/>
  <result pre="or proteins have been identified as targets for chemotherapy [13]." exact="Viral" post="replication cycle includes viral adsorption, viral cell fusion, reverse"/>
  <result pre="identified as targets for chemotherapy [13]. Viral replication cycle includes" exact="viral" post="adsorption, viral cell fusion, reverse transcription, integration, translation and"/>
  <result pre="targets for chemotherapy [13]. Viral replication cycle includes viral adsorption," exact="viral" post="cell fusion, reverse transcription, integration, translation and other steps,"/>
  <result pre="used as targets for antiviral drugs [14]. In addition, specific" exact="viral" post="enzymes which involve the synthesis of viral DNA, RNA"/>
  <result pre="In addition, specific viral enzymes which involve the synthesis of" exact="viral" post="DNA, RNA and glycoproteins are also potential targets [15]."/>
  <result pre="also potential targets [15]. For example, acyclovir disturbs some key" exact="herpes" post="virus enzymes that have an affinity for nucleotide analogues"/>
  <result pre="affinity for nucleotide analogues [16]. Despite the successful understanding of" exact="viral" post="proliferation cycle and comprehensive studies for suitable vaccines and"/>
  <result pre="cycle and comprehensive studies for suitable vaccines and treatments against" exact="viral" post="infections over the past half of century, still several"/>
  <result pre="and comprehensive studies for suitable vaccines and treatments against viral" exact="infections" post="over the past half of century, still several infections"/>
  <result pre="viral infections over the past half of century, still several" exact="infections" post="such as HIV afflict a substantial proportion of the"/>
  <result pre="generations [17]. There is no definite vaccine against numerous prevalent" exact="viral" post="infections, including most respiratory-tract viruses, HSV-1 and HSV-2 or"/>
  <result pre="available antiviral agents by different viruses such as the HIV" exact="type 1" post="or HSV-1 has always been a serious impediment to"/>
  <result pre="HSV-1 has always been a serious impediment to treatment of" exact="viral" post="infections, stimulating the search for new efficient molecules [16,17]."/>
  <result pre="great attention from scholars and practitioners, as many marine derived" exact="secondary" post="metabolites with evidently anti-inflammatory, antitumor, antimicrobial, antiviral, antimalarial, and"/>
  <result pre="Marine microbes have become a promising reservoir of new antivirus" exact="secondary" post="metabolites [22]. There are about 1 million microorganisms in"/>
  <result pre="competition, they have metabolized some specific molecules to obtain extremely" exact="limited" post="resources [24]. These secondary metabolites can chemically be divided"/>
  <result pre="some specific molecules to obtain extremely limited resources [24]. These" exact="secondary" post="metabolites can chemically be divided into alkaloids, peptides, polyketides,"/>
  <result pre="utilized as anti-HIV compound in preclinical development [25]. However, only" exact="limited" post="natural compounds discovered from marine microbes have been used"/>
  <result pre="(48%) anti-HSV (33%), and others (19%) (Fig.Â 1 ). These" exact="secondary" post="metabolites were mainly isolated from marine microbes Aspergillus, Penicillium"/>
  <result pre="3) were obtained from marine microbes sampled in China. 18" exact="secondary" post="metabolites, such as truncateol O (16) and R-wailupemycin K"/>
  <result pre="known antiviral compounds reported from 2009 to 2019. TableÂ 1" exact="Secondary" post="metabolites with anti-H1N1 and anti-H3N2 activities from marine microbes."/>
  <result pre="Jcma1F17 IC50Â =Â 17.0Â Î¼MÂ (H3N2 virus) [46] TableÂ 2" exact="Secondary" post="metabolites with anti-HSV activities from marine microbes. TableÂ 2"/>
  <result pre="0.1, 0.01, 0.1Â Î¼g/mL, resp. (HSV-1 virus) [61] TableÂ 3" exact="Secondary" post="metabolites with other antivirus activities from marine microbes. TableÂ"/>
  <result pre="marine-derived Streptomyces youssoufiensis OUC6819 discovered that heterologous expression of the" exact="type III" post="polyketide synthase (PKS) gene vioA resulted in production of"/>
  <result pre="In addition, only compound 13 showed effective inhibition against H1N1" exact="viral" post="neuraminidase (NA), and docking of two isomers (13 and"/>
  <result pre="2.2 Anti-HSV virus compounds HSV-1 is regularly correlative to oral-facial" exact="infections" post="and encephalitis, whereas HSV-2 frequently causes genital ulcers worldwide"/>
  <result pre="a unique incubation period and physiological reactivation characteristics [49]. The" exact="chronic" post="incubation period makes the host susceptible to repeated attacks"/>
  <result pre="10) [58]. Compounds 52 and 53 exhibited evidently inhibition against" exact="herpes" post="simplex virus type 1 (HSV-1) with IC50 values of"/>
  <result pre="52 and 53 exhibited evidently inhibition against herpes simplex virus" exact="type 1" post="(HSV-1) with IC50 values of 9.5 and 19.8Â Î¼M"/>
  <result pre="concentrations for their antiviral activity against Herpes simplex virus (HSV)" exact="type I." post="These compounds were found to showed inhibitory effect with"/>
  <result pre="antiretroviral drugs were on the market for the treatment of" exact="HIV infection" post="and divided into six main groups: integrase inhibitors, protease"/>
  <result pre="drugs were on the market for the treatment of HIV" exact="infection" post="and divided into six main groups: integrase inhibitors, protease"/>
  <result pre="65 showed anti-HIV effects by blocking HIV replication in one-cycle" exact="infection" post="assay with IC50 values of 39.0 and 16.1Â Î¼M,"/>
  <result pre="activity than the data raising from the isolated compounds, the" exact="lower" post="cytotoxicity of the collected compounds (IC50Â &amp;gt;Â 100Â Î¼M)"/>
  <result pre="broad-spectrum inhibitory activities against different types of viruses, including human" exact="immunodeficiency" post="virus (HIV), and hepatitis C virus (HCV) [66]. Compound"/>
  <result pre="different types of viruses, including human immunodeficiency virus (HIV), and" exact="hepatitis C" post="virus (HCV) [66]. Compound 66 showed inhibitory activities against"/>
  <result pre="anti-HCV activities. RSV is considered to be the major pediatric" exact="respiratory" post="pathogen, triggered by G protein combining host cell receptors"/>
  <result pre="triggered by G protein combining host cell receptors [68]. Only" exact="limited" post="therapeutic compounds for RSV have been reported, such as"/>
  <result pre="[70]. Compound 70 was tested for its inhibitory activity towards" exact="respiratory" post="syncytial virus (RSV), displaying potential anti-RSV activity with IC50"/>
  <result pre="China Sea, Guangxi Province, China in 2008 [71]. The isolated" exact="secondary" post="metabolites were evaluated for their anti-virus activities [71]. The"/>
  <result pre="evaluated for their anti-virus activities [71]. The antiviral activity against" exact="respiratory" post="syncytial virus (RSV) induced cytopathogenicity in human laryngeal carcinoma"/>
  <result pre="activity against respiratory syncytial virus (RSV) induced cytopathogenicity in human" exact="laryngeal carcinoma" post="(Hep-2) cell was determined by the cythopathic effect (CPE)"/>
  <result pre="against respiratory syncytial virus (RSV) induced cytopathogenicity in human laryngeal" exact="carcinoma" post="(Hep-2) cell was determined by the cythopathic effect (CPE)"/>
  <result pre="of compounds 70â€&quot;72 with anti-RSV activities. EV71 viruses can cause" exact="acute" post="neurological disease in children, leading to heart and lung"/>
  <result pre="compounds 70â€&quot;72 with anti-RSV activities. EV71 viruses can cause acute" exact="neurological disease" post="in children, leading to heart and lung failure [72]."/>
  <result pre="70â€&quot;72 with anti-RSV activities. EV71 viruses can cause acute neurological" exact="disease" post="in children, leading to heart and lung failure [72]."/>
  <result pre="viruses can cause acute neurological disease in children, leading to" exact="heart" post="and lung failure [72]. Despite broad research with extensive"/>
  <result pre="is vital to develop new antivirus drugs due to the" exact="absence of" post="proper treatment or vaccination for DENF [76]. A known"/>
  <result pre="inner tissue of the soft coral Lobophytum crassum which was" exact="acquired" post="from Hainan Sanya National Coral Reef Reserve, China [77]."/>
  <result pre="the symptoms, currently, there is no therapy to cure this" exact="disease" post="[78]. Debromoaplysiatoxin (76,Fig.Â 17 ) and anhydrodebromoaplysiatoxin (77,Fig.Â 17),"/>
  <result pre="a step in the CHIKV replication cycle which occurred after" exact="viral" post="entry. Compounds 76 and 78 may represent a new"/>
  <result pre="Chemical structures of compounds 76â€&quot;78 with anti-CHIKV activities. The Western" exact="Equine" post="Encephalitis Virus (WEEV) belongs to the encephalitic alpha viruses,"/>
  <result pre="structures of compounds 76â€&quot;78 with anti-CHIKV activities. The Western Equine" exact="Encephalitis" post="Virus (WEEV) belongs to the encephalitic alpha viruses, which"/>
  <result pre="which can directly infect neurons leading to CNS inflammation and" exact="neuronal" post="destruction. It can cause severe diseases in human with"/>
  <result pre="currently no licensed vaccines or antivirus drugs for alpha virus" exact="infections" post="[80]. Chemical investment of the extract of marine-derived Streptomyces"/>
  <result pre="of people. Nevertheless, few treatments are available for deadly virus" exact="infectious diseases" post="till now. Additionally, a great large of antiviral drugs"/>
  <result pre="a great large of antiviral drugs have been described with" exact="viral" post="resistance, which remains an unsolved challenge for antivirus therapy"/>
  <result pre="inÂ vitro studies showed promising results on these compounds, a" exact="limited" post="account of inÂ vivo studies has been performed to"/>
  <result pre="2ChowE.J.DoyleJ.D.UyekiT.M.Influenza virus-related critical illness: prevention, diagnosis, treatmentCrit. Care23201921431189475 3XuX.ZhangY.LiQ.Characteristics of" exact="herpes" post="simplex virus infection and pathogenesis suggest a strategy for"/>
  <result pre="critical illness: prevention, diagnosis, treatmentCrit. Care23201921431189475 3XuX.ZhangY.LiQ.Characteristics of herpes simplex" exact="virus infection" post="and pathogenesis suggest a strategy for vaccine developmentRev. Med."/>
  <result pre="illness: prevention, diagnosis, treatmentCrit. Care23201921431189475 3XuX.ZhangY.LiQ.Characteristics of herpes simplex virus" exact="infection" post="and pathogenesis suggest a strategy for vaccine developmentRev. Med."/>
  <result pre="for the cure of HIV infectionEnferm. Infecc. Microbiol. ClÃ­n.37201926527329510860 5PrianteE.CavicchioloM.E.BaraldiE.RSV" exact="infection" post="and respiratory sequelaeMinerva Pediatr.70201862363330379052 6JinY.ZhangR.WuW.DuanG.Antiviral and inflammatory cellular signaling"/>
  <result pre="cure of HIV infectionEnferm. Infecc. Microbiol. ClÃ­n.37201926527329510860 5PrianteE.CavicchioloM.E.BaraldiE.RSV infection and" exact="respiratory" post="sequelaeMinerva Pediatr.70201862363330379052 6JinY.ZhangR.WuW.DuanG.Antiviral and inflammatory cellular signaling associated with"/>
  <result pre="therapyNat. Rev. Immunol.20202026927032273594 10NeiderudC.J.How urbanization affects the epidemiology of emerging" exact="infectious" post="diseasesInfect. Ecol. Epidemiol.520152706026112265 11StrasfeldL.ChouS.Antiviral drug resistance: mechanisms and clinical"/>
  <result pre="agentsJ.Â Pharmacol. Exp. Therapeut.2972001110 16SchneiderS.M.PritchardS.M.WudiriG.A.TrammellC.E.NicolaA.V.Early steps in Herpes Simplex Virus" exact="infection" post="blocked by a proteasome inhibitormBio102019e00732 17YombiJ.C.MertesH.Treatment as prevention for"/>
  <result pre="diversityCurr. Biol.272017R489R49428586685 24LeeY.M.KimM.LiH.ZhangP.BaoB.LeeK.J.JungJ.H.Marine-derived Aspergillus species as a source of bioactive" exact="secondary" post="metabolitesMar. Biotechnol.15201349951923709045 25Yasuhara-BellJ.LuY.Marine compounds and their antiviral activitiesAntivir. Res.86201023124020338196"/>
  <result pre="interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1" exact="swine flu" post="virusBiochem. Biophys. Res. Commun.386200943243619523442 30HutchinsonE.C.Influenza virusTrends Microbiol.26201880981029909041 31KimH.WebsterR.G.WebbyR.J.Influenza virus:"/>
  <result pre="improved anti-influenza A virus activity by heterologous expression of a" exact="type III" post="PKS gene in a marine Streptomyces strainBioorg. Med. Chem."/>
  <result pre="mangrove rhizosphere soil-derived fungus Aspergillus terreus Gwq-48 with anti-influenza A" exact="viral" post="(H1N1) activityBioorg. Med. Chem. Lett.2320131776177823411074 39CheQ.QiaoL.HanX.LiuY.WangW.GuQ.ZhuT.LiD.Anthranosides Aâ€&quot;C, anthranilate derivatives"/>
  <result pre="fungus Aspergillus ochraceus Jcma1F17MedChemComm52014701705 47LodiG.PettiS.The controversial natural history of oral" exact="herpes" post="simplex virus type 1 infection.Oral Dis.2520191850186531733122 48GrovesM.J.Genital herpes: a"/>
  <result pre="Jcma1F17MedChemComm52014701705 47LodiG.PettiS.The controversial natural history of oral herpes simplex virus" exact="type 1" post="infection.Oral Dis.2520191850186531733122 48GrovesM.J.Genital herpes: a reviewAm. Fam. Physician93201692893427281837 49SauerbreiA.SchmittS.ScheperT.BrandstÃ¤dtA.WutzlerP.Seroprevalence"/>
  <result pre="infection.Oral Dis.2520191850186531733122 48GrovesM.J.Genital herpes: a reviewAm. Fam. Physician93201692893427281837 49SauerbreiA.SchmittS.ScheperT.BrandstÃ¤dtA.WutzlerP.Seroprevalence of" exact="herpes" post="simplex virus type 1 and type 2 in Thuringia,"/>
  <result pre="herpes: a reviewAm. Fam. Physician93201692893427281837 49SauerbreiA.SchmittS.ScheperT.BrandstÃ¤dtA.WutzlerP.Seroprevalence of herpes simplex virus" exact="type 1" post="and type 2 in Thuringia, Germany, 1999 to 2006Euro"/>
  <result pre="Fam. Physician93201692893427281837 49SauerbreiA.SchmittS.ScheperT.BrandstÃ¤dtA.WutzlerP.Seroprevalence of herpes simplex virus type 1 and" exact="type 2" post="in Thuringia, Germany, 1999 to 2006Euro Surveill.16201120005 50BirkmannA.ZimmermannH.HSV antivirals"/>
  <result pre="- current and future treatment optionsCurr. Opin. Virol.18201691326897058 51PiretJ.BoivinG.Resistance of" exact="herpes" post="simplex viruses to nucleoside analogues: mechanisms, prevalence, and managementAntimicrob."/>
  <result pre="HIV finally maturedThe Lancet HIV62019e561âˆ’e563 65KantersS.MillsE.J.ThorlundK.BucherH.C.IoannidisJ.P.A.Antiretroviral therapy for initial human" exact="immunodeficiency" post="virus/AIDS treatment: critical appraisal of the evidence from over"/>
  <result pre="fungus Aspergillus Niger SCSIO Jcsw6F30Bioorg. Med. Chem. Lett26201636136526711143 68Boyoglu-BarnumS.ChirkovaT.AndersonL.J.Biology of" exact="infection" post="and disease pathogenesis to guide RSV vaccine developmentFront. Immunol.102019167531402910"/>
  <result pre="Niger SCSIO Jcsw6F30Bioorg. Med. Chem. Lett26201636136526711143 68Boyoglu-BarnumS.ChirkovaT.AndersonL.J.Biology of infection and" exact="disease" post="pathogenesis to guide RSV vaccine developmentFront. Immunol.102019167531402910 69FeldmanS.A.HendryR.M.BeelerJ.A.Identification of"/>
  <result pre="Immunol.102019167531402910 69FeldmanS.A.HendryR.M.BeelerJ.A.Identification of a linear heparin binding domain for human" exact="respiratory" post="syncytial virus attachment glycoprotein GJ.Â Virol.7319996610661710400758 70YuM.GuanF.CaoF.JiaY.WangC.AÂ new antiviral"/>
  <result pre="towards antiviral therapies against enterovirus 71Drug Discov. Today1520101041105120974282 74ChenS.WangJ.WangZ.LinX.ZhaoB.KaliaperumalK.LiaoX.TuZ.LiJ.XuS.LiuY.Structurally diverse" exact="secondary" post="metabolites from a deep-sea-derived fungus Penicillium chrysogenum SCSIO 41001"/>
  <result pre="activity of scequinadoline A against dengue virusMar. Drugs162018229 78StavenessD.AbdelnabiR.NearK.E.NakagawaY.NeytsJ.DelangL.LeyssenP.WenderP.A.Inhibition of" exact="chikungunya" post="virus-induced cell death by salicylate-derived bryostatin analogues provides additional"/>
  <result pre="provides additional evidence for a PKC-independent pathwayJ.Â Nat. Prod.79201668068426900711 79GuptaD.K.KaurP.LeongS.T.TanL.T.PrinsepM.R.ChuJ.J.Anti-Chikungunya" exact="viral" post="activities of aplysiatoxin-related compounds from the marine cyanobacterium Trichodesmium"/>
 </snippets>
</snippetsTree>
